University Health Network, Toronto: Melanoma trials

The registry lists 21 Melanoma studies with University Health Network, Toronto as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 6No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled TrialNot yet recruitingNCT07820033Phase 2
• Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)RecruitingNCT07524114
• Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic MelanomaRecruitingNCT07112170Not applicable
• Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk MelanomaRecruitingNCT06319196Phase 2
• Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)RecruitingNCT05403177
• Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)RecruitingNCT05196087
• Genomic Investigation of Unusual RespondersRecruitingNCT03740503
• Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT03702309
• Ontario-wide Cancer TArgeted Nucleic Acid EvaluationRecruitingNCT02906943
• Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced CancerActive, not recruitingNCT06416085Phase 2
• A Study to Test the Benefit of Vitamin B5 in Patients With MelanomaActive, not recruitingNCT06377111Phase 1
• Breathomics as Predictive Biomarker for Checkpoint Inhibitor ResponseCompletedNCT04146064
• The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) TrialCompletedNCT03158935Phase 1
• Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid TumorsActive, not recruitingNCT02869217Phase 1
• Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic TherapiesCompletedNCT02724488
• Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02644369Phase 2
• Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant MelanomaCompletedNCT02251314
• Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With MelanomaCompletedNCT01883323Phase 2
• Study of Ipilimumab in the Immune SystemCompletedNCT01715077Not applicable
• Feasibility Study of Genomic Profiling Methods and Timing in Tumor SamplesCompletedNCT01703585
• Ultrasound Biomicroscopy - ApoptosisCompletedNCT00188370Phase 2